Young-Ho Lee
Chief Executive Officer presso Immunique Co. Ltd.
Posizioni attive di Young-Ho Lee
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Hanyang University | Corporate Officer/Principal | - | - |
Immunique Co. Ltd.
 Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Chief Executive Officer | - | - |
Storia della carriera di Young-Ho Lee
Precedenti posizioni note di Young-Ho Lee
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NANOENTEK, INC. | Director/Board Member | 24/03/2022 | 08/09/2023 |
| Independent Dir/Board Member | 24/03/2022 | 08/09/2023 |
Formazione di Young-Ho Lee
| Hanyang University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Corea del Sud | 4 |
Posizioni
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NANOENTEK, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
- Borsa valori
- Insiders
- Young-Ho Lee
- Esperienza
